课题基金 / 基金详情

Targeting the Estrogen Pathway for the Prevention and Treatment of LAM

Targeting the Estrogen Pathway for the Prevention and Treatment of LAM
靶向雌激素途径预防和治疗 LAM
批准号:
9171443
负责人:
Jane Yu
金额:
$4.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-09 至 2018-03-31

项目摘要

项目成果

Jane Yu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This proposal is focused on the molecular mechanisms underlying the pathogenesis of lymphangioleiomyomatosis (LAM), a devastating disease affecting young women. The reasons that LAM affects women almost exclusively are not yet clearly defined. We have discovered that estrogen promotes the survival and lung colonization of intravenously injected Tsc2-null ELT3 cells. Our central hypothesis is that estrogen promotes the survival of tuberin-deficient cells, thereby allowing LAM cells to accumulate in the lungs and lymphatics. To address this hypothesis, we propose three Specific Aims: Aim 1. To identify the molecular mechanisms through which estrogen enhances the survival and metastasis of tuberin-deficient cells. We will test the hypothesis that Bim (Bcl-2 interacting mediator of cell death) is a mediator of estrogen-promoted survival and identify the signaling events that underlie the enhanced levels of Bim in estrogen-treated ELT3 cells. Aim 2. To determine whether estrogen enhances the survival of LAM-derived cells in vitro and in vivo. We will determine whether E2 promotes the survival of LAM-derived cells in vitro in either detached or attached conditions using a novel approach to distinguish between LAM cells and stromal cells, and determine whether E2 enhances the survival and/or metastasis of LAM-derived cells in vivo. Aim 3. To determine whether inhibition of MEK1/2 and ER( leads to a regression of established lung metastasis of ELT3 cells. We will determine whether targeting MEK1/2 or ER( prevents further progression or induces regression of E2-induced lung metastasis of ELT3 cells. We will identify additional molecular determinants of E2-dependent survival of ELT3 cells using a modern proteomic approach.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.
胰岛素生长因子结合蛋白2介导淋巴管平滑肌瘤病的进展。
DOI: 10.18632/oncotarget.16695
发表时间: 2017
期刊: Oncotarget
影响因子: --
作者: [Li,Xiangke, Liu,Xiaolei, Zhang,Linda, Li,Chenggang, Zhang,Erik, Ma,Wang, Fan,Qingxia, Yu,JaneJ]
通讯作者: Yu,JaneJ
Reply: hormonally targeted therapy for women with lymphangioleiomyomatosis.
答复:针对女性淋巴管平滑肌瘤病的激素靶向治疗。
DOI: 10.1165/rcmb.2013-0324le
发表时间: 2014
期刊: American journal of respiratory cell and molecular biology
影响因子: 6.4
作者: [Yu,Jane]
通讯作者: Yu,Jane
DOI: 10.1513/pats.200909-104js
发表时间: 2010-02-01
期刊: Proceedings of the American Thoracic Society
影响因子: --
作者: [Yu, Jane, Parkhitko, Andrey A, Henske, Elizabeth Petri]
通讯作者: Henske, Elizabeth Petri
DOI: 10.1089/lrb.2009.0020
发表时间: 2010-03
期刊: Lymphatic research and biology
影响因子: 1.4
作者: [Jane J. Yu;E. Henske]
通讯作者: Jane J. Yu;E. Henske
Polo-like kinase 1 and sphingosine-1-phosphate circuitry enhances TSC-mutant cell survival
  • 批准号:
    10915745
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2023
  • 负责人:
    Jane Yu
  • 依托单位:
Targeting prostaglandin biosynthesis and action in lymphangioleiomyomatosis
  • 批准号:
    9367516
  • 项目类别:
  • 资助金额:
    $65.11万
  • 财政年份:
    2017
  • 负责人:
    Jane Yu
  • 依托单位:
Prostaglandin biosynthesis: a novel therapeutic target in TSC disorders
  • 批准号:
    8760750
  • 项目类别:
  • 资助金额:
    $26.53万
  • 财政年份:
    2014
  • 负责人:
    Jane Yu
  • 依托单位:
Prostaglandin biosynthesis: a novel therapeutic target in TSC disorders
  • 批准号:
    8917941
  • 项目类别:
  • 资助金额:
    $23.7万
  • 财政年份:
    2014
  • 负责人:
    Jane Yu
  • 依托单位:
国内基金
海外基金
Estrogen/NDRG2/Na+/K+-ATPase调控通路在唾液生成和雌激素缺乏诱发口干症中的作用研究